Fig. 3From: Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patientsEvolution of the disease burden and the economic cost over time for all stakeholders. This graphic represents how decrease in negative health and socio-economic outcomes on patients and families are associated with an increase of the burden and economic costs on health care systems and payersBack to article page